Back to Peptides
Regeneration

BPC-157

Body-repair peptide derived from human gastric protective proteins.

About BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protective protein found in human gastric juice. It has shown remarkable regenerative properties across multiple tissues: muscle, tendon, ligament, bone and the nervous system. It works by promoting angiogenesis (the formation of new blood vessels), modulating nitric-oxide production and protecting the vascular endothelium.

How it works

  • 1Mechanism: promotes angiogenesis and modulates nitric oxide, accelerating the repair of soft tissue.
  • 2Typical protocol: subcutaneous injection near the injury site, one to two times a day.
  • 3Expected timeline: improvements in inflammation by around 2 weeks; noticeable tissue repair between weeks 4 and 8.
  • 4Follow-up: clinical review at 4 weeks to adjust the protocol or extend the cycle.

Suggested protocol: 4–12 week cycle depending on the condition, with reassessment at 4 weeks.

Benefits

  • Accelerated repair of tendons and ligaments
  • Healing of gastric and intestinal ulcers
  • Protection of the nervous system and brain
  • Reduction of systemic inflammation
  • Improved wound healing
  • Protection against liver damage

Safety and compliance

Protocol supervised by Dr. Xavier Guzmán

Professional license (cédula) 15115581, verifiable with SEP

  • COFEPRIS-regulated clinic. Peptides prepared in licensed compounding pharmacies.
  • Investigational / clinical use under medical prescription. Not FDA-approved as an over-the-counter treatment.
  • Widely studied in preclinical models with a favorable safety profile
  • Published studies show a favorable tolerability profile
  • Requires medical supervision for correct dosing

Contraindications

  • Pregnancy and breastfeeding
  • Active cancer or recent history of cancer
  • Under 18 years of age

Frequently asked questions about BPC-157

Answers specific to this peptide. For questions about the program in general, visit our general FAQ.

Yes. BPC-157 is especially useful for chronic tendinopathies, ligament injuries and musculoskeletal pain that has not responded to physical therapy. The physician determines whether it is the right protocol for your case.

Yes. A subcutaneous injection near the injured area is often part of the protocol, but the exact technique is determined by your physician based on the region and the type of tissue involved.

Patients report improvements in inflammation and pain within the first 2 weeks. Deeper tissue repair usually consolidates between weeks 4 and 8.

Yes. BPC-157 is frequently combined with TB-500 in regeneration protocols. Your physician decides the optimal synergy for your goals.

Published studies show a favorable tolerability profile. Some patients notice mild, transient redness at the injection site.

Price

Ask at consultation

Personalized quote after medical evaluation

1 month

start

Ask at consultation

3 months

Ask at consultation

6 months

Ask at consultation

Administration

Subcutaneous injection or oral application

Duration

4–12 weeks depending on the condition

Book a consultation

Prior medical evaluation required.

Join 500+ patients who have transformed their health with Regeneris

Take the Next Step For Your Health Today

Schedule your complimentary medical evaluation and find out whether a molecular optimization program is right for you. At your pace, calm and clear.

Limited evaluation slots available this monthNext available appointment: Tomorrow at 10:00 AM
Nationwide shippingFlexible cancellationAt your pacePhysicians 24/7
Regeneris

Molecular Regenerative Medicine, Cancún, Mexico

COFEPRIS-licensed clinic · RFC: RTH221227M19

Regulatory Information

COFEPRIS Health Notice: 2323025036X00098

COFEPRIS Advertising Authorization: 2323022002A00053

Tax ID (RFC): RTH221227M19

Health Officer in Charge: Misael González Montenegro, Biotechnologist · Cédula (Mexican professional license) 13226492 , verifiable at the federal registry.

Pharmacovigilance contact: farmacovigilancia@regeneristherapy.com

Compliant with NOM-220-SSA1-2024 for pharmacovigilance and adverse event reporting.

This site does not diagnose, treat, cure, or prevent any disease. Molecular regenerative therapies are prescription medications that require a physician evaluation. Individual results may vary. Consult a licensed physician before starting any treatment. All care is delivered in Mexico under Mexican regulatory frameworks; we do not practice medicine in the United States.

Personal data is handled in accordance with Mexico's Federal Law on the Protection of Personal Data Held by Private Parties (LFPDPPP). See our Privacy Notice.

© 2026 Regeneris Therapy. All rights reserved.

BPC-157, Therapeutic Peptides | Regeneris Therapy